These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26433699)

  • 21. [Cost-effectiveness analysis of sofosbuvir-simeprevir regimens for chronic hepatitis C genotype 1 patients with advanced fibrosis].
    Mar J; Mar-Barrutia L; Gimeno-Ballester V; San Miguel R
    Med Clin (Barc); 2016 Jan; 146(2):61-4. PubMed ID: 26654558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hep C Calculator: an online tool for cost-effectiveness analysis of DAAs.
    Chhatwal J; Chen Q; Bethea ED; Ladd MA; Mueller PP; Hutin Y; Aggarwal R
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):819. PubMed ID: 30507463
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness of viral hepatitis B & C treatment.
    Toy M
    Best Pract Res Clin Gastroenterol; 2013 Dec; 27(6):973-85. PubMed ID: 24182615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does patient cost sharing for HCV drugs make sense?
    Lakdawalla DN; Linthicum MT; Vanderpuye-Orgle J
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP188-90. PubMed ID: 27266947
    [No Abstract]   [Full Text] [Related]  

  • 25. [Cost-effectiveness of antiviral therapy for chronic hepatitis C patients in prevention of hepatocellular cancer ].
    Yoshida H; Tateishi R; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):511-4. PubMed ID: 15359852
    [No Abstract]   [Full Text] [Related]  

  • 26. The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing.
    Shafran SD
    Can J Gastroenterol Hepatol; 2015; 29(1):46-8. PubMed ID: 25706574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What is (cost) effective in patients with chronic hepatitis C virus infection?
    Zeuzem S
    Eur J Gastroenterol Hepatol; 2001 May; 13(5):473-6. PubMed ID: 11396523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Newest Treatments for Hepatitis C: How Can We Manage Sustainability?
    Messori A
    Clin Infect Dis; 2015 Dec; 61(12):1891-2. PubMed ID: 26261204
    [No Abstract]   [Full Text] [Related]  

  • 29. Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.
    Chen CP; Cheng CY; Zou H; Cheng CH; Cheng SH; Chen CK; Chen CH; Bair MJ
    J Microbiol Immunol Infect; 2019 Aug; 52(4):556-562. PubMed ID: 30360951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.
    Rein DB; Wittenborn JS; Smith BD; Liffmann DK; Ward JW
    Clin Infect Dis; 2015 Jul; 61(2):157-68. PubMed ID: 25778747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Is more expensive always better?].
    Drenth JP
    Ned Tijdschr Geneeskd; 2014; 159():A8556. PubMed ID: 25534272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cost-effectiveness of chronic hepatitis C treatment in Spain].
    Haj-Ali Saflo O; Hernández Guijo JM
    Gastroenterol Hepatol; 2009; 32(7):472-82. PubMed ID: 19615787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of treatment for chronic hepatitis C.
    Koff RS
    J Hepatol; 1999; 31 Suppl 1():255-8. PubMed ID: 10622598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Editorial commentary: getting smart in how we pay for HCV drugs: KAOS vs CONTROL.
    Saag MS
    Clin Infect Dis; 2015 Jul; 61(2):169-70. PubMed ID: 25778748
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost effectiveness of hepatitis C treatments: Need for a comprehensive evaluation.
    DeNardo Z; Choi M; Stiller M; Buechel D
    Kaohsiung J Med Sci; 2017 Nov; 33(11):584-585. PubMed ID: 29050677
    [No Abstract]   [Full Text] [Related]  

  • 36. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding Cost and Value in Hepatitis C Therapy.
    Linas BP
    Top Antivir Med; 2016; 24(2):93-97. PubMed ID: 27841979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C.
    Chidi AP; Rogal S; Bryce CL; Fine MJ; Good CB; Myaskovsky L; Rustgi VK; Tsung A; Smith KJ
    Hepatology; 2016 Feb; 63(2):428-36. PubMed ID: 26524695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C.
    Buti M; Casado MA; Fosbrook L; Wong JB; Esteban R
    J Hepatol; 2000 Oct; 33(4):651-8. PubMed ID: 11059872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C.
    Gellad ZF; Reed SD; Muir AJ
    Antivir Ther; 2012; 17(6 Pt B):1189-99. PubMed ID: 23186646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.